van Horssen R - Search Results

1

Cytokine detection in cells and tissues: complicated lessons from proEMAP/p43 and EMAP-II.

van Horssen R, Rens JA, ten Hagen TL. van Horssen R, et al. Inflamm Res. 2008 Jul;57(7):297-9. doi: 10.1007/s00011-007-7184-1. Inflamm Res. 2008. PMID: 18607540 No abstract available.

2

EMAP-II facilitates TNF-R1 apoptotic signalling in endothelial cells and induces TRADD mobilization.

van Horssen R, Rens JA, Schipper D, Eggermont AM, ten Hagen TL. van Horssen R, et al. Apoptosis. 2006 Dec;11(12):2137-45. doi: 10.1007/s10495-006-0284-5. Apoptosis. 2006. PMID: 17051333

3

Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion.

van Horssen R, Rens JA, Brunstein F, Guns V, van Gils M, Hagen TL, Eggermont AM. van Horssen R, et al. Among authors: van gils m. Int J Cancer. 2006 Sep 15;119(6):1481-90. doi: 10.1002/ijc.21973. Int J Cancer. 2006. PMID: 16615114

4

Involvement of endothelial monocyte activating polypeptide II in tumor necrosis factor-alpha-based anti-cancer therapy.

Lans TE, Van Horssen R, Eggermont AM, Ten Hagen TL. Lans TE, et al. Among authors: van horssen r. Anticancer Res. 2004 Jul-Aug;24(4):2243-8. Anticancer Res. 2004. PMID: 15330168 Free article. Review.

5

Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma.

Lans TE, ten Hagen TL, van Horssen R, Wu PC, van Tiel ST, Libutti SK, Alexander HR, Eggermont AM. Lans TE, et al. Among authors: van tiel st, van horssen r. Ann Surg Oncol. 2002 Oct;9(8):812-9. doi: 10.1007/BF02574505. Ann Surg Oncol. 2002. PMID: 12374666 Free article.

6

TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.

van Horssen R, Ten Hagen TL, Eggermont AM. van Horssen R, et al. Oncologist. 2006 Apr;11(4):397-408. doi: 10.1634/theoncologist.11-4-397. Oncologist. 2006. PMID: 16614236 Free article. Review.

7

Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes.

van Horssen R, Eggermont AM, ten Hagen TL. van Horssen R, et al. Cytokine Growth Factor Rev. 2006 Oct;17(5):339-48. doi: 10.1016/j.cytogfr.2006.08.001. Epub 2006 Sep 1. Cytokine Growth Factor Rev. 2006. PMID: 16945568 Review.

8

E-cadherin promotor methylation and mutation are inversely related to motility capacity of breast cancer cells.

van Horssen R, Hollestelle A, Rens JA, Eggermont AM, Schutte M, Ten Hagen TL. van Horssen R, et al. Breast Cancer Res Treat. 2012 Nov;136(2):365-77. doi: 10.1007/s10549-012-2261-8. Epub 2012 Sep 29. Breast Cancer Res Treat. 2012. PMID: 23053649

9

Crossing barriers: the new dimension of 2D cell migration assays.

Van Horssen R, ten Hagen TL. Van Horssen R, et al. J Cell Physiol. 2011 Jan;226(1):288-90. doi: 10.1002/jcp.22330. J Cell Physiol. 2011. PMID: 20658519

10

Differential effects of matrix and growth factors on endothelial and fibroblast motility: application of a modified cell migration assay.

van Horssen R, Galjart N, Rens JA, Eggermont AM, ten Hagen TL. van Horssen R, et al. J Cell Biochem. 2006 Dec 15;99(6):1536-52. doi: 10.1002/jcb.20994. J Cell Biochem. 2006. PMID: 16817234

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters